Axsome Therapeutics announces AXS-05 achieves primary endpoint in phase 2 trial
Axsome Therapeutics announced that Duke University has completed its topline analysis of the Phase 2 trial of AXS-05 for smoking cessation treatment. The analysis showed that AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking compared to bupropion. April 15, 2019